Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values
- 31 May 2007
- journal article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 58 (1) , 9-17
- https://doi.org/10.1016/j.diagmicrobio.2007.01.020
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Contemporary Prevalence of BRO β-Lactamases in Moraxella catarrhalis : Report from the SENTRY Antimicrobial Surveillance Program (North America, 1997 to 2004)Journal of Clinical Microbiology, 2006
- The effect of implementing the British Thoracic Society community-acquired pneumonia guidelines on antibiotic prescribing and costs in a UK teaching hospitalClinical Microbiology & Infection, 2006
- Antibiotic Prescription for Community-Acquired Pneumonia in the Intensive Care Unit: Impact of Adherence to Infectious Diseases Society of America Guidelines on SurvivalClinical Infectious Diseases, 2005
- Bactericidal activity of garenoxacin tested by kill-curve methodology against wild type and QRDR mutant strains of Streptococcus pneumoniaeDiagnostic Microbiology and Infectious Disease, 2004
- Pharmacodynamics of the New Des-F(6)-QuinoloneGarenoxacin in a Murine Thigh InfectionModelAntimicrobial Agents and Chemotherapy, 2003
- Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniaeDiagnostic Microbiology and Infectious Disease, 2003
- Development of the quinolonesJournal of Antimicrobial Chemotherapy, 2003
- Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance programDiagnostic Microbiology and Infectious Disease, 2003
- Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjectsJournal of Antimicrobial Chemotherapy, 2003
- Decreased Susceptibility ofStreptococcus pneumoniaeto Fluoroquinolones in CanadaNew England Journal of Medicine, 1999